Movatterモバイル変換


[0]ホーム

URL:


WO2024077062A3 - Mitochondria-targeted n-acetylcysteine and analogs - Google Patents

Mitochondria-targeted n-acetylcysteine and analogs
Download PDF

Info

Publication number
WO2024077062A3
WO2024077062A3PCT/US2023/075944US2023075944WWO2024077062A3WO 2024077062 A3WO2024077062 A3WO 2024077062A3US 2023075944 WUS2023075944 WUS 2023075944WWO 2024077062 A3WO2024077062 A3WO 2024077062A3
Authority
WO
WIPO (PCT)
Prior art keywords
mitochondria
acetylcysteine
targeted
present compounds
compounds
Prior art date
Application number
PCT/US2023/075944
Other languages
French (fr)
Other versions
WO2024077062A2 (en
Inventor
Balaraman Kalyanaraman
Micael Joel Hardy
Gang Cheng
Original Assignee
The Medical College Of Wisconsin, Inc.
Aix-Marseille Universite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medical College Of Wisconsin, Inc., Aix-Marseille UniversitefiledCriticalThe Medical College Of Wisconsin, Inc.
Priority to EP23875746.2ApriorityCriticalpatent/EP4598516A2/en
Publication of WO2024077062A2publicationCriticalpatent/WO2024077062A2/en
Publication of WO2024077062A3publicationCriticalpatent/WO2024077062A3/en
Anticipated expirationlegal-statusCritical
Ceasedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The present disclosure provides mitochondria-targeted N-acetylcysteine compounds and pharmaceutical compositions thereof. The present compounds may be useful for treating cancer and enhancing CAR-T cell therapy. The present compounds may be isotopically labeled, which may be useful for labeling and analyzing a sample. The present compounds may target mitochondria in carcer cells and have improved anti-tumor effect and reduced toxicity.
PCT/US2023/0759442022-10-052023-10-04Mitochondria-targeted n-acetylcysteine and analogsCeasedWO2024077062A2 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
EP23875746.2AEP4598516A2 (en)2022-10-052023-10-04Mitochondria-targeted n-acetylcysteine and analogs

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US202263413461P2022-10-052022-10-05
US63/413,4612022-10-05

Publications (2)

Publication NumberPublication Date
WO2024077062A2 WO2024077062A2 (en)2024-04-11
WO2024077062A3true WO2024077062A3 (en)2024-05-30

Family

ID=90609050

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/US2023/075944CeasedWO2024077062A2 (en)2022-10-052023-10-04Mitochondria-targeted n-acetylcysteine and analogs

Country Status (2)

CountryLink
EP (1)EP4598516A2 (en)
WO (1)WO2024077062A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20050147555A1 (en)*2002-03-012005-07-07Hong FanMethods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20060094121A1 (en)*2002-11-182006-05-04Ludwig Institute For Cancer ResearchMethod for analysing amino acids, peptides and proteins
US20080248959A1 (en)*2006-07-212008-10-09Neose Technologies, Inc.Glycosylation of peptides via o-linked glycosylation sequences
US20200163970A1 (en)*2017-02-032020-05-28Tohoku UniversityHeterocyclic compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20050147555A1 (en)*2002-03-012005-07-07Hong FanMethods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20060094121A1 (en)*2002-11-182006-05-04Ludwig Institute For Cancer ResearchMethod for analysing amino acids, peptides and proteins
US20080248959A1 (en)*2006-07-212008-10-09Neose Technologies, Inc.Glycosylation of peptides via o-linked glycosylation sequences
US20200163970A1 (en)*2017-02-032020-05-28Tohoku UniversityHeterocyclic compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 14 June 2012 (2012-06-14), ANONYMOUS: "(2R)-2-acetamido-N-methyl-3-methylsulfanylpropanamide | C7H14N2O2S", XP093177684, Database accession no. CID 57182754*
DATABASE PubChem 4 December 2011 (2011-12-04), ANONYMOUS: "(2R)-2-acetamido-N-propyl-3-sulfanylpropanamide | C8H16N2O2S", XP093177686, Database accession no. CID 54082229*

Also Published As

Publication numberPublication date
WO2024077062A2 (en)2024-04-11
EP4598516A2 (en)2025-08-13

Similar Documents

PublicationPublication DateTitle
PotęgaGlutathione-mediated conjugation of anticancer drugs: an overview of reaction mechanisms and biological significance for drug detoxification and bioactivation
Becker et al.Laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) in elemental imaging of biological tissues and in proteomics
Pongratz et al.Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy
Codreanu et al.Alkylation damage by lipid electrophiles targets functional protein systems
Steele et al.Chronic inflammation alters production and release of glutathione and related thiols in human U373 astroglial cells
WO2007047668A3 (en)Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells
Albert et al.Speciation analysis of the antirheumatic agent Auranofin and its thiol adducts by LC/ESI-MS and LC/ICP-MS
Najafi et al.Protective effects of alpha lipoic acid on high glucose-induced neurotoxicity in PC12 cells
Persichilli et al.Plasma thiols levels in alzheimer's disease mice under diet-induced hyperhomocysteinemia: effect of s-adenosylmethionine and superoxide-dismutase supplementation
Nachimuthu et al.L-Ergothioneine: a potential bioactive compound from edible mushrooms
Solovieva et al.Hydroxycobalamin catalyzes the oxidation of diethyldithiocarbamate and increases its cytotoxicity independently of copper ions
García-Calvo et al.In-vitro and in-vivo evaluation of the molecular mechanisms involved in the toxicity associated to CdSe/ZnS quantum dots exposure
Narayanan et al.Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation
Unal et al.Antigenotoxic effect of lipoic acid against mitomycin-C in human lymphocyte cultures
WO2024077062A3 (en)Mitochondria-targeted n-acetylcysteine and analogs
Richardson et al.A direct, ratiometric, and quantitative MALDI–MS assay for protein methyltransferases and acetyltransferases
Khatal et al.Validated HPTLC method for simultaneous quantitation of paracetamol, diclofenac potassium, and famotidine in tablet formulation
Jenke et al.HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer
Spasojević et al.The reaction of methionine with hydroxyl radical: reactive intermediates and methanethiol production
Mandal et al.A SEC-HPLC-ICP MS hyphenated technique for identification of sulfur-containing arsenic metabolites in biological samples
Teichert et al.Identification and quantitation of the N-acetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride
Wu et al.Physiological, proteomic and metabolomic analysis provide insights into Ca2+ tolerance in Drynaria roosii leaves
Perjési et al.(E)-2-Benzylidenebenzocyclanones: Part VII. Investigation of the conjugation reaction of two cytotoxic cyclic chalcone analogues with glutathione: an HPLC–MS study
Isobe et al.Direct microanalysis by negative ion fast atom bombardment mass spectrometry
Ohyama et al.A toxicoproteomic study on cardioprotective effects of pre-administration of docetaxel in a mouse model of adriamycin-induced cardiotoxicity

Legal Events

DateCodeTitleDescription
121Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number:23875746

Country of ref document:EP

Kind code of ref document:A2

ENPEntry into the national phase

Ref document number:2025519723

Country of ref document:JP

Kind code of ref document:A

WWEWipo information: entry into national phase

Ref document number:2025519723

Country of ref document:JP

NENPNon-entry into the national phase

Ref country code:DE

WWEWipo information: entry into national phase

Ref document number:2023875746

Country of ref document:EP

ENPEntry into the national phase

Ref document number:2023875746

Country of ref document:EP

Effective date:20250506

121Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number:23875746

Country of ref document:EP

Kind code of ref document:A2

WWPWipo information: published in national office

Ref document number:2023875746

Country of ref document:EP


[8]ページ先頭

©2009-2025 Movatter.jp